CD47/SIRPA-BLOCKING AGENT ALX148
Composite Lymphoma
M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Composite Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rituximab M.D. Anderson Cancer Center | Phase 1/2 | B |
Lenalidomide M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Cyclophosphamide University of Washington | Phase 1 | CC |
Prednisone University of Washington | Phase 1 | CC |
Pembrolizumab University of Washington | Phase 1 | CC |
Vincristine Sulfate University of Washington | Phase 1 | CC |
Adriamycin University of Washington | Phase 1 | CC |
Same molecule, other indications
CD47/SIRPA-BLOCKING AGENT ALX148 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →